title: Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure.
abstract: We investigated the effect of electrical cardioversion of atrial fibrillation in patients with heart failure. The study group consisted of 24 patients with mild to moderate heart failure [13 men, mean age 67+/-7 years, mean peak oxygen consumption (peak VO2) 16.3+/-2.8 ml/min/kg] and chronic atrial fibrillation (median duration 19 (1-228) months). Patients were stable on digoxin, diuretics, nitrates and angiotensin converting enzyme inhibitors; no prophylaxis with antiarrhythmics was started after cardioversion. Cardioversion was unsuccessful in 6 patients; of the 18 patients in whom sinus rhythm was obtained 9 had a relapse of atrial fibrillation within 6 weeks after cardioversion. The remaining 9 patients with maintenance of sinus rhythm and the 15 (6+9) patients with atrial fibrillation at follow-up after 6 weeks did not differ with respect to any baseline characteristic, including age, peak VO2, duration of atrial fibrillation, echocardiographic left ventricular and left atrial dimensions, plasma atrial natriuretic peptide and norepinephrine. In the patients with maintenance of sinus rhythm, baseline measurements were repeated at follow-up. Peak VO2 did not change significantly (16.7+/-2.8 to 17.6+/-3.3 ml/min/kg, P=0.29); also, echo parameters, atrial natriuretic peptide and norepinephrine were not significantly affected. These results indicate that it is difficult to achieve lasting sinus rhythm through electrical cardioversion in patients with atrial fibrillation and mild to moderate heart failure. Moreover, in patients with maintenance of sinus rhythm after cardioversion no significant benefit in terms of peak VO2, cardiac dimensions, and neurohumoral status is to be expected. Hence, indiscriminate cardioversion of atrial fibrillation in the setting of heart failure does not appear to be useful.
authors.affiliation: Department of Cardiology, Thorax Center, University Hospital Groningen, The Netherlands.
authors.forename: M P
authors.initials: MP
authors.lastname: van den Berg
authors.forename: A E
authors.initials: AE
authors.lastname: Tuinenburg
authors.forename: D J
authors.initials: DJ
authors.lastname: van Veldhuisen
authors.forename: P J
authors.initials: PJ
authors.lastname: de Kam
authors.forename: H J
authors.initials: HJ
authors.lastname: Crijns
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D009320:Atrial Natriuretic Factor / Q000097:blood; D004452:Echocardiography; D004554:Electric Countershock; D015716:Electrocardiography, Ambulatory; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D006339:Heart Rate; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010101:Oxygen Consumption; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D009320:Atrial Natriuretic Factor; D009638:Norepinephrine